Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,524.00    4.00 (0.26%)
Bid:
1,518.00
Ask:
1,520.00
Spread: 2.00 (0.132%)
Market Cap: £3.21b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 Dec 2007 14:05

Hikma Pharmaceuticals Plc17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the sale of 320,000 ordinary sharesof 10 pence each in the capital of the Company, received by him pursuant to anexercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executedon 14 December 2007. The shares sold represented 0.187% of the outstanding sharecapital of the Company, and following the sale Mr Darwazah remains interested in1,706,506 ordinary shares, representing 0.999% of the share capital of theCompany. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relates toDTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Apr 20164:22 pmRNSDirector/PDMR Shareholding
20th Apr 20164:00 pmRNSDirector/PDMR Shareholding
19th Apr 20164:14 pmRNSDirector/PDMR Shareholding
19th Apr 201612:57 pmRNSDirector/PDMR Shareholding
12th Apr 201610:02 amRNSDirector/PDMR Shareholding
8th Apr 20167:00 amRNSUpdate on ANDA for Generic Advair Diskus®
8th Apr 20167:00 amRNSPortfolio Update - VR315 US
7th Apr 20164:08 pmRNSDirector/PDMR Shareholding
7th Apr 201611:41 amRNSAnnual Information Update
7th Apr 201610:54 amRNSAnnual Financial Report
6th Apr 20164:11 pmRNSBlocklisting Interim Review
5th Apr 20164:13 pmRNSDirector/PDMR Shareholding
31st Mar 20165:37 pmRNSDirector/PDMR Shareholding
29th Mar 20169:36 amRNSDirector/PDMR Shareholding
21st Mar 20162:54 pmRNSDirector/PDMR Shareholding
17th Mar 20163:25 pmRNSDirector/PDMR Shareholding
16th Mar 20167:00 amRNSFinal Results
3rd Mar 20169:25 amRNSNotice of Results
29th Feb 20162:01 pmRNSHolding(s) in Company
29th Feb 20161:59 pmRNSHolding(s) in Company
29th Feb 20161:47 pmRNSTotal Voting Rights
29th Feb 20161:46 pmRNSRoxane Acquisition Close
22nd Feb 20169:52 amRNSDirectorate Change
19th Feb 201612:55 pmRNSEGM Statement
11th Feb 201612:43 pmRNSHolding(s) in Company
11th Feb 201612:19 pmRNSCirc re. Roxane Acquisition
10th Feb 201610:38 amRNSHikma Analyst and Investor Call
10th Feb 20167:00 amRNSCirc re. Roxane Acquisition
22nd Jan 20162:04 pmRNSCirc re. Roxane Acquisition and EGM
7th Jan 201611:08 amRNSTotal Voting Rights
24th Dec 20157:52 amRNSShareholders' Agreement and Board Appointment
17th Dec 20159:38 amRNSTotal Voting Rights
3rd Dec 20159:30 amRNSDirector/PDMR Shareholding
25th Nov 20158:45 amRNSHikma announces sale of Ben Venue manufacturing
24th Nov 20157:00 amRNSHolding(s) in Company
18th Nov 20157:00 amRNSResolution to FDA Warning Letter
16th Nov 20153:04 pmRNSHolding(s) in Company
11th Nov 20154:16 pmRNSHolding(s) in Company
10th Nov 20152:43 pmRNSHolding(s) in Company
2nd Nov 20157:00 amRNSTrading Statement
22nd Oct 20157:00 amRNSBlock Listing of Share
19th Oct 201511:11 amRNSHolding(s) in Company
12th Oct 201510:25 amRNSBlocklisting Interim Review
8th Oct 20154:10 pmRNSTotal Voting Rights
18th Sep 20152:40 pmRNSAudit Tender
16th Sep 20154:08 pmRNSTotal Voting Rights
11th Sep 20153:47 pmRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSHikma agrees to acquire EIMC United Pharmaceutical
27th Aug 20154:02 pmRNSDirector/PDMR Shareholding
27th Aug 20153:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.